請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99367完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤 | zh_TW |
| dc.contributor.advisor | Tsai-Kun Li | en |
| dc.contributor.author | 姜沛妤 | zh_TW |
| dc.contributor.author | Pei-Yu Chiang | en |
| dc.date.accessioned | 2025-09-09T16:10:33Z | - |
| dc.date.available | 2025-09-10 | - |
| dc.date.copyright | 2025-09-09 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-08-01 | - |
| dc.identifier.citation | Angelantonio ED, Bhupathiraju S, Wormser D et al. (2016) Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 388: 776-786.
Parekh PJ, Balart LA, Johnson DA et al. (2015) Gut Microbiome and Obesity. Clin Transl Gastroenterol 6(6). Khan S, Luck H, Winer S et al. (2021) Emerging concepts in intestinal immune control of obesity-related metabolic disease. Nat Commun 12(2598). Winer DA, Luck H, Tsai S, and Winer S et al. (2016). The Intestinal Immune System in Obesity and Insulin Resistance. Cell Metab 23: 413–426. Gallausiaux CM, Marinelli l, Blottière HM et al. (2020) SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc 80: 37-49. Chew NWS, Ng CH, Tan DJH et al. The global burden of metabolic disease: Data from 2000 to 2019. (2023) Cell Metabolism 35(3):414–428. Wang W, Hu M, Liu H et al. Global burden of ischemic heart disease attributable to metabolic risk factors: findings from the Global Burden of Disease Study 2019. (2021) Cell Metab 33(10):1943-1956. Paone P, Suriano F, Jian C, et al. Prebiotic oligofructose protects against high-fat diet-induced obesity by changing the gut microbiota, intestinal mucus production, glycosylation and secretion. (2022) Gut Microbes 14(1). Cani PD, de Vos WM. Next-generation beneficial microbes: The case of Akkermansia muciniphila. (2017) Frontiers in Microbiology 8(1765). Cani PD, Osto M, Geurts L et al. Involvement of gut microbiota in the development of low‑grade inflammation and type 2 diabetes associated with obesity. (2012) Gut Microbes 3(4):279–288. Zhang X, Wang D, Bo T et al. Bifidobacterium pseudolongum reduces triglycerides by modulating gut microbiota in mice fed high‑fat food. (2020) J Steroid Biochem Mol Biol 198(105602). Yang G, Hong E, Oh S et al. Non viable Lactobacillus johnsonii JNU3402 protects against diet induced obesity. (2020) Foods 9(10). Mager LF, Burkhard R, Pett N et al. Microbiome derived inosine modulates response to checkpoint inhibitor immunotherapy. (2020) Science 369(6500): 1481–1487. Yoon HS, Cho CH, Yun MS et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. (2021) Nat Microbio 6(5): 563-573. Chelakkot C, Choi Y, Kim D K et al. Akkermansia muciniphila–derived extracellular vesicles influence gut permeability through the regulation of tight junctions. (2018) Experimental & Molecular Medicine 50(450). Qu D, Chen M, Zhu H et al. Akkermansia muciniphila and its outer membrane protein Amuc_1100 prevent high fat diet induced nonalcoholic fatty liver disease in mice. (2023) Biochemical and Biophysical Research Communications 648(149131). Pei T, Wang M, Hu R et al. Akkermansia muciniphila ameliorates chronic kidney disease interstitial fibrosis via the gut-renal axis. (2023) Microb Pathog 174(105891). Jun Shi. Akkermansia muciniphila attenuates LPS induced acute kidney injury by inhibiting TLR4/NF κB pathway. (2022) FEMS Microbiol Lett 369. Plovier H, Everard A, Druart C et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. (2017) Nat Med 23(1): 107–113. Hou K, Wu ZX , Chen XY et al. Microbiota in health and diseases. (2022) Signal Transduct Target Ther 7(135). Zhang Y, Zhang J, Yang X et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. (2025) Cell Metab 37(3): 592–605 Wu W, Kaicen W, Bian X, et al. Akkermansia muciniphila alleviates high fat diet related metabolic associated fatty liver disease by modulating gut microbiota and bile acids. (2023) Microbial Biotechnology 16(10), 1924–1939. Chang L, Rongrong M, Han L, et al. Akkermansia muciniphila ameliorates fatty liver through microbiota-derived α ketoisovaleric acid metabolism and hepatic PI3K/Akt signaling. (2025) iScience, 28(5). Zhan Y, Wang L, Chen X, et al. Probiotics and their metabolites reduce oxidative stress in middle-aged mice. (2023) Journal of Functional Foods, 100, 105401. Smith J, Wang L. Distribution and roles of Ligilactobacillus murinus in hosts. (2023) Journal of Microbial Ecology, 47(2), 123–135. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99367 | - |
| dc.description.abstract | 現代生活型態下的飲食改變,例如高脂飲食與低膳食纖維攝入,是導致肥胖與代謝症候群盛行率上升的主要原因之一。在肥胖與代謝症候群的發病機制中,腸道免疫系統已被視為代謝穩態調控的重要角色。此外,近年來科學家們逐漸發現腸道微生物組在改善代謝症候群與發炎性疾病、提升傳統癌症治療療效等方面具有潛在作用。因此,本研究針對高脂飲食誘導肥胖小鼠,施以三種益生菌(包括兩種傳統益生菌:擬長雙歧桿菌(Bifidobacterium pseudolongum)與約氏乳桿菌(Lactobacillus johnsonii),以及一種次世代益生菌:阿克曼菌(Akkermansia
muciniphila)與益生元進行輔助處理,測量血清葡萄糖、腎功能、肝功能及組織脂質累積等指標。結果顯示,以阿克曼菌與益生元共同處理的小鼠,在所有參數,包括組織脂質累積上均表現出更顯著的改善。我們進一步分析此組別小鼠的腸道菌群,並與對照組比較,以探討改善效果是否與菌群組成變動相關。結果發現,不同處理組間之菌相有顯著差異。總結而言,我們確認益生菌與益生元補充於高脂飲食誘導之損傷中具有正向改善作用,顯示此類補充具備潛在代謝健康益處,可為人類提供福祉。 | zh_TW |
| dc.description.abstract | The increasing prevalence of obesity and metabolic syndrome highlights the need for focusing on identification, implementation, and evaluation of evidence-based interventions to address this problem. There are several underlying factors contribute to the pathogenesis. Dietary changes associated with modern lifestyles, such as highfat diets and low-fiber intake, are key factors contributing to the increasing rates of obesity and metabolic syndrome. There is a huge need to ameliorate the damage caused by dietary changes. The intestinal immune system has emerged as an important regulator of metabolic homeostasis. In recent years, scientists have discovered the potential role of microbiota. They help improve metabolic syndrome, inflammatory disease, enhance the efficacy of traditional cancer therapy, and more. Therefore, in our study, we measured serum glucose, kidney function, liver function, and tissue lipid accumulation in HFD-induced mice treated with three probiotics— including two traditional probiotics, Bifidobacterium pseudolongum and Lactobacillus johnsonii—and one next-generation probiotic, Akkermansia muciniphila, as well as prebiotics. The results showed that the group treated with Akkermansia muciniphila and prebiotics had better improvements in all parameters, including tissue lipid accumulation. We then assessed the gut microbiota of this group and compared it with the control group to determine whether the improvements were related to changes in the microbiota. The results indicated that there were differences between the groups, depending on the treatments they received. In conclusion, we confirm that supplementation with probiotics and prebiotics has beneficial effects on HFD-induced damage, indicating potential metabolic benefits in the human body. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-09-09T16:10:33Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-09-09T16:10:33Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員審定書 i
中文摘要 ii ABSTRACT iii CONTENT v INTRODUCTION 1 SPECIFIC AIM 5 MATERIALS and METHODS 6 Animals and treatment 6 Culture of Akkermansia muciniphila 7 Culture of Bifidobacterium pseudolongum and Lactobacilius johnsonii 7 The measurement of OD600 8 DNA extraction 8 PCR amplification of the 16S rRNA gene 9 Histological analysis 9 The analysis of the composition of gut microbiota 10 Statistical analyses 10 RESULTS 11 1.The Correlation Between OD600 and CFU Counting. 11 2.Co-administration of A. muciniph 11 3.No significant differences were observed in kidney tissue between G1 and G9; however, liver lipid accumulation was reduced in G9. 13 4.A. muciniphila could not colonize the mice gut, even with supplementation of prebiotics or other probiotics. 14 5.Significant changes in microbiota structure between G1, G3, G8, and G9 were observed in -diversity rather than -diversity. 15 FIGURES 18 Figure 1. The Correlation Between OD600 and CFU Counting of B. pseudolongum, L johnsonii, and A. muciniphila. 18 Figure 2. Co-administration of A. muciniphila and prebiotic treatment improved the body weight and serum glucose of HFD-fed mice. 19 Figure 3. Co-administration of A. muciniphila and prebiotic treatment improved the liver function of HFD-fed mice. 20 Figure 4. Co-administration of A. muciniphila and prebiotic treatment improved the kidney function of HFD-fed mice. 21 Figure 5. Co-administration of A. muciniphila and prebiotic treatment improved the metabolism of HFD-fed mice. 22 Figure 6. No significant differences were observed in kidney tissue between G1 and G9; however, liver fat accumulation was reduced in G9. 23 Figure 7. A. muciniphila could not colonize the mice gut, even with supplementation of prebiotics or other probiotics. 24 Figure 8. Significant changes in microbiota structure during the treatment in G1, G3, G8, and G9 were observed in -diversity rather than -diversity. 25 Figure 9. Significant changes in microbiota structure between G1, G3, G8, and G9 were observed in -diversity rather than -diversity. 26 Figure 10. The heatmap illustrates the composition of metabolic-related gut microbiota. 27 DISCUSSION 28 TABLES 31 Table 1. The composition of prebiotics powder. 31 Table 2. Sequence of primers used in qRT-PCR analysis. 32 REFERENCES 33 | - |
| dc.language.iso | en | - |
| dc.subject | 高脂飲食 | zh_TW |
| dc.subject | 長雙歧桿菌 | zh_TW |
| dc.subject | 約氏乳桿菌 | zh_TW |
| dc.subject | 嗜黏蛋白阿克曼菌 | zh_TW |
| dc.subject | 益生元 | zh_TW |
| dc.subject | 多樣性 | zh_TW |
| dc.subject | 代謝症候群 | zh_TW |
| dc.subject | 肝腎功能 | zh_TW |
| dc.subject | b-diversity | en |
| dc.subject | Prebiotics | en |
| dc.subject | Akkermansia muciniphila | en |
| dc.subject | Lactobacillus johnsonii | en |
| dc.subject | Bifidobacterium pseudolongum | en |
| dc.subject | Hepatorenal Function | en |
| dc.subject | High-fat diets | en |
| dc.subject | Metabolic syndrome | en |
| dc.subject | a-diversity | en |
| dc.title | 比菲德氏菌、乳酸桿菌與阿克曼氏菌對高脂飲食誘導小鼠代謝參數及肝腎功能之影響 | zh_TW |
| dc.title | Effects of Bifidobacterium, Lactobacillus, and Akkermansia on Metabolic Parameters and Hepatorenal Function in High-Fat Diet Mice | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 鄧述諄;倪衍玄 | zh_TW |
| dc.contributor.oralexamcommittee | Shu-Chun Teng;Yen-Hsuan Ni | en |
| dc.subject.keyword | 代謝症候群,高脂飲食,肝腎功能,長雙歧桿菌,約氏乳桿菌,嗜黏蛋白阿克曼菌,益生元,多樣性, | zh_TW |
| dc.subject.keyword | Metabolic syndrome,High-fat diets,Hepatorenal Function,Bifidobacterium pseudolongum,Lactobacillus johnsonii,Akkermansia muciniphila,Prebiotics,a-diversity,b-diversity, | en |
| dc.relation.page | 36 | - |
| dc.identifier.doi | 10.6342/NTU202503188 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2025-08-04 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 微生物學研究所 | - |
| dc.date.embargo-lift | N/A | - |
| 顯示於系所單位: | 微生物學科所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 3.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
